Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Barr on Novel Combination Strategies in CLL

May 7th 2020

Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester, discusses novel combination strategies in chronic lymphocytic leukemia (CLL).

Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL

May 6th 2020

Paul M. Barr, MD, discusses the findings from a phase 1/2 trial and the evolution toward triplet therapies in chronic lymphocytic leukemia.

Dr. Pagel on Ongoing Research With BTK Inhibitors in CLL

May 6th 2020

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses ongoing research with BTK inhibitors in chronic lymphocytic leukemia (CLL).

Umbralisib Plus Ublituximab Improves PFS in Frontline and Relapsed/Refractory CLL

May 5th 2020

A doublet combining umbralisib and ublituximab improved progression-free survival in patients with chronic lymphocytic leukemia.

Dr. Awan on Remaining Questions With BTK Inhibitors and Anti-CD20 Combos in CLL

May 2nd 2020

Farrukh Awan, MD, discusses remaining questions regarding the use of BTK inhibitors and CD20-directed monoclonal antibodies in chronic lymphocytic leukemia.

FDA Approves Ibrutinib/Rituximab for Frontline CLL/SLL

April 21st 2020

The FDA has approved an expanded indication of ibrutinib for use in combination with rituximab for the frontline treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Mato Highlights Promise of Investigational Immunotherapeutics in CLL

April 16th 2020

Anthony R. Mato, MD, MSCE, discusses the different research efforts that are being made with immunotherapy in chronic lymphocytic leukemia.

Questions With BTK Inhibitors and Anti-CD20 Combos Require Further Study in CLL

April 10th 2020

Farrukh Awan, MD, discusses the rationale for combining BTK inhibitors with CD20-directed monoclonal antibodies in CLL, sequencing challenges, and remaining questions in the chronic lymphocytic leukemia.

Dr. Woyach on the Utility of Time-Limited Therapies in CLL

April 9th 2020

Jennifer Woyach, MD, discusses the utility of time-limited therapies in chronic lymphocytic leukemia.

Dr. Mato on the Efficacy of Fixed-Duration Venetoclax-Based Combo in CLL

April 8th 2020

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial, which evaluated the efficacy of fixed-duration treatment with venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia.

Dr. Awan on Future of Combo Regimens in CLL Treatment Paradigm

April 8th 2020

Farrukh Awan, MD, discusses questions regarding combination therapies in chronic lymphocytic leukemia.

Acalabrutinib Triplet Impresses in Frontline CLL, Advances to Phase III Study

April 7th 2020

The addition of acalabrutinib (Calquence) to venetoclax (Venclexta) and obinutuzumab (Gazyva) was shown to be highly active in patients with newly diagnosed chronic lymphocytic leukemia, eliciting deep and durable responses.

Dr. Danilov on Venetoclax Plus BTK Inhibitors in CLL

April 7th 2020

Alexey V. Danilov, MD, PhD, discusses the potential for combining venetoclax with novel BTK inhibitors in chronic lymphocytic leukemia.

Dr. Raphael on Addressing the Risk of Tumor Lysis Syndrome in CLL

April 4th 2020

Bruce G. Raphael, MD, discusses the risk of tumor lysis syndrome in chronic lymphocytic leukemia.

Dr. Choi on the Utility of Duvelisib in CLL

April 4th 2020

Michael Choi, MD, discusses the utility of duvelisib in chronic lymphocytic leukemia.

Dr. Choi on Impact of Frontline Treatment Decisions on Relapsed/Refractory CLL

April 3rd 2020

Michael Choi, MD, discusses how up-front treatment decisions impact what options can be given in the relapsed/refractory setting for patients with chronic lymphocytic leukemia.

Dr. Awan on Novel Strategies Under Exploration in Relapsed/Refractory CLL

April 2nd 2020

Farrukh Awan, MD, discusses novel approaches under investigation in relapsed/refractory chronic lymphocytic leukemia.

An Expert Assessment of Available BTK Inhibitors Within the CLL Treatment Spectrum

March 20th 2020

Brad S. Kahl, MD, discusses the use of BTK inhibitors, which have revolutionized the treatment paradigm in chronic lymphocytic leukemia.

Investigators Pursue Less-Toxic Treatment in Frontline CLL

March 16th 2020

Investigators are evaluating whether the addition of venetoclax to a standard doublet regimen in chronic lymphocytic leukemia can induce responses deep enough to allow patients to not only suspend long-term treatment but also avoid associated toxicity.

Optimizing Frontline Therapy With Cost-Savings Considerations in CLL

March 12th 2020

Matthew S. Davids, MD, MMSc, discusses data that were presented with novel combinations in chronic lymphocytic leukemia at the 2019 ASH Annual Meeting and the importance of conducting cost-effective analyses.